isosorbide dinitrate has been researched along with cilostazol in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Appleton, JP; Bath, PM; Blair, GW; Boyd, J; Dooley, R; Doubal, F; Flaherty, K; Hamilton, I; Law, ZK; Richardson, C; Shi, Y; Shuler, K; Sprigg, N; Stringer, M; Thrippleton, MJ; Wardlaw, JM | 1 |
| Appleton, JP; Bath, PM; Blair, GW; Chappell, F; Doubal, FN; Flaherty, K; Hamilton, I; Janssen, E; Shi, Y; Stringer, MS; Thrippleton, MJ; Wardlaw, JM | 1 |
1 review(s) available for isosorbide dinitrate and cilostazol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for isosorbide dinitrate and cilostazol
| Article | Year |
|---|---|
Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mon
Topics: Age Factors; Cerebral Small Vessel Diseases; Cilostazol; Cognition Disorders; Dementia; Double-Blind Method; Female; Follow-Up Studies; Humans; Isosorbide Dinitrate; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Severity of Illness Index; Treatment Outcome; United Kingdom; Vasodilator Agents | 2018 |
Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial.
Topics: Aged; Cerebral Small Vessel Diseases; Cilostazol; Female; Hemodynamics; Humans; Isosorbide Dinitrate; Lipoproteins; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome; Vasodilator Agents | 2022 |